In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America

In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America

Autor Gales, Ana Cristina Autor UNIFESP Google Scholar
Jones, Ronald N. Google Scholar
Andrade, Soraya Sgambatti Autor UNIFESP Google Scholar
Pereira, Andrea dos Santos Autor UNIFESP Google Scholar
Sader, Helio Silva Autor UNIFESP Google Scholar
Instituição Universidade Federal de São Paulo (UNIFESP)
Department of Medicine
The JMI Laboratories
Resumo The in vitro activity of tigecycline (former GAR-936), a new semisynthetic tetracycline, was evaluated in comparison with tetracycline and other antimicrobial agents. MATERIAL AND METHODS: A total of 1,326 contemporary clinical isolates collected from the Latin American region were collected in 2000-2002 period and tested with microdilution broth according to the CLSI guidelines. The bacterial pathogens evaluated included Staphylococcus aureus (505), Streptococcus pneumoniae (269), coagulase-negative staphylococci (CoNS; 227), Haemophilus influenzae (129), Enterococcus spp. (80), Moraxella catarrhalis (54), beta-haemolytic streptococci (28), viridans group streptococci (26), and Neisseria meningitidis (8) RESULTS:Tigecycline demonstrated excellent activity against all Gram-positive cocci, with 90% of penicillin-resistant S. pneumoniae strains being inhibited at 0.12 µg/mL, while the same isolates had an MIC90 of > 16 µg/mL for tetracycline. All Enterococcus spp. were inhibited at 0.25 µg/mL of tigecycline. Tigecycline (MIC50, 0.25 µg/mL) was eight-fold more potent than minocycline (MIC50, 2 µg/mL) against oxacillin-resistant S. aureus (ORSA); all ORSA were inhibited at < 2 µg/mL of tigecycline. Tigecycline demonstrated excellent activity (MIC50, 0.5 µg/mL) against CoNS with reduced susceptibility to teicoplanin (MIC, 16 µg/mL). Tigecycline also showed high potency against respiratory pathogens such as M. catarrhalis (MIC50, 0.12 µg/mL) and H. influenzae (MIC50, 0.5 µg/mL). No tigecycline resistant isolates were detected when the proposed susceptible breakpoints (< 4 µg/mL) was applied. CONCLUSIONS: This results indicate that tigecycline has potent in vitro activity against clinically important pathogenic bacteria, including Gram-positive isolates resistant to both tetracycline and minocycline.
Assunto Antimicrobial susceptibility
Latin America and SENTRY
Idioma Inglês
Data 2005-10-01
Publicado em Brazilian Journal of Infectious Diseases. Brazilian Society of Infectious Diseases, v. 9, n. 5, p. 348-356, 2005.
ISSN 1413-8670 (Sherpa/Romeo)
Editor Brazilian Society of Infectious Diseases
Extensão 348-356
Direito de acesso Acesso aberto Open Access
Tipo Artigo
SciELO S1413-86702005000500001 (estatísticas na SciELO)

Mostrar registro completo

Arquivos deste item

Nome: S1413-86702005000500001.pdf
Tamanho: 47.86Kb
Formato: PDF

Este item aparece na(s) seguinte(s) coleção(s)